source
- ADARx aims for $318 million IPO as TRexBio and Retension also fileADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
- Walgreens Specialty Pharmacy highlights holistic support to boost oncology medication adherenceAdvances in oncology are moving care out of the clinic and into patients' homes, with treatments becoming more personalized. This shift means patients often manage complex drug schedules themselves…